Evidence map›Paper›PMID 41707283›Full record

ArticleEuropean journal of medicinal chemistry2026

Tailoring cariprazine for dual disorders via secondary pharmacophore optimization.

Caleb D Vogt, Julie Sanchez, Alessandro Bonifazi, Elizabeth Saab, Arina Ranjit, Rana Rais, J Robert Lane, Amy Hauck Newman

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in European journal of medicinal chemistry, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors.

Caleb D VogtMedicinal Chemistry Section, Molecular Targets and Medications Discovery Branch, National Institute on Drug Abuse - Intramural Research Program, National Institutes of Health, 333 Cassell Drive, Baltimore, MD, 21224, United States.
Julie SanchezDivision of Physiology, Pharmacology and Neuroscience, School of Life Sciences, Queen's Medical Centre, University of Nottingham, Nottingham, NG7 2UH, United Kingdom; Centre of Membrane Proteins and Receptors, Universities of Birmingham and Nottingham, Midlands, NG2 7AG, United Kingdom.
Alessandro BonifaziMedicinal Chemistry Section, Molecular Targets and Medications Discovery Branch, National Institute on Drug Abuse - Intramural Research Program, National Institutes of Health, 333 Cassell Drive, Baltimore, MD, 21224, United States; Department of Pharmacology and Toxicology, Center for Addiction Sciences and Therapeutics, University of Texas Medical Branch, Galveston, TX, 77555, United States.
Elizabeth SaabMedicinal Chemistry Section, Molecular Targets and Medications Discovery Branch, National Institute on Drug Abuse - Intramural Research Program, National Institutes of Health, 333 Cassell Drive, Baltimore, MD, 21224, United States.
Arina RanjitDepartment of Neurology, Johns Hopkins Drug Discovery, The Johns Hopkins University School of Medicine, 855 North Wolfe Street, Baltimore, MD, 21205, United States.
Rana RaisDepartment of Neurology, Johns Hopkins Drug Discovery, The Johns Hopkins University School of Medicine, 855 North Wolfe Street, Baltimore, MD, 21205, United States.
J Robert LaneDivision of Physiology, Pharmacology and Neuroscience, School of Life Sciences, Queen's Medical Centre, University of Nottingham, Nottingham, NG7 2UH, United Kingdom; Centre of Membrane Proteins and Receptors, Universities of Birmingham and Nottingham, Midlands, NG2 7AG, United Kingdom.
Amy Hauck NewmanMedicinal Chemistry Section, Molecular Targets and Medications Discovery Branch, National Institute on Drug Abuse - Intramural Research Program, National Institutes of Health, 333 Cassell Drive, Baltimore, MD, 21224, United States. Electronic address: anewman@intra.nida.nih.gov.

Funding

NOVEL DOPAMINE D3 RECEPTOR LIGANDSZ01DA000424 · NIDA · NATIONAL INSTITUTE ON DRUG ABUSE · PI NEWMAN, AMY HAUCK · 1999 to 2008
$1.8M
Intramural NIH HHS Z01 DA000424
6 · The paper itself

Abstract

Cariprazine is an approved drug used to treat schizophrenia, bipolar disorder, and (more recently) major depression. These serious mental illnesses are often comorbid with psychostimulant use disorders, for which no pharmacotherapeutic is currently approved. Based on preclinical data and multiple case studies, cariprazine demonstrates significant potential as a treatment for such dual disorders. Notably, this drug acts as a high-affinity (K

Indexed as

Antipsychotic AgentsBipolar DisorderMajor Depressive DisorderPiperazinesReceptors, Dopamine D3SchizophreniaAnimalsDose-Response Relationship, DrugHumansMicrosomes, LiverMolecular StructurePharmacophoreRatsReceptors, Dopamine D2Structure-Activity RelationshipAntipsychotic AgentscariprazinePiperazinesReceptors, Dopamine D2Receptors, Dopamine D3Bipolar disorderBitopic ligandCariprazineCocaineDopamine D(2) receptorDopamine D(3) receptorDual disorderMajor depressionMethamphetaminePsychostimulant use disorderSchizophreniaSubstance use disorder

Identifiers

PMID41707283
PMCPMC12976872

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.